Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Kevin M. Huang(The Ohio State University), Alex Sparreboom(The Ohio State University), Tarek Magdy(Northwestern University), Joanne Wang(University of Washington), Ingrid M. Bonilla(The Ohio State University), Pearlly S. Yan(The Ohio State University), Stefan Oswald(University of Rostock), Sakima A. Smith(The Ohio State University Wexner Medical Center), Duncan F. DiGiacomo(The Ohio State University), Ralf Bundschuh(The Ohio State University), Vincenzo Coppola(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Muhammad Erfan Uddin(The Ohio State University), Alexander Pan, Qiang Fu(City University of Hong Kong), Markus Keiser(Universitätsmedizin Greifswald), Moray J. Campbell(Cedars-Sinai Medical Center), Daniel Addison(The University of Texas Southwestern Medical Center), Anne T. Nies(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Alice A. Gibson(The Ohio State University), Megan Zavorka Thomas(The Ohio State University), Eric D. Eisenmann(The Ohio State University), Cynthia A. Carnes(The Ohio State University), Sharyn D. Baker(The Ohio State University), Kara N. Corps(The Ohio State University), Shuiying Hu(The Ohio State University), Maryam B. Lustberg(Yale Cancer Center), Sherry H. Xia(The Ohio State University), Paul W. Burridge(Northwestern University), Yang Li(Institute of Vegetables and Flowers), Marcus Otter(Universitätsmedizin Greifswald), Yan Jin(The Ohio State University), Taosheng Chen(St. Jude Children's Research Hospital)
Cited by 67
Related Papers
Cremophor EL
|European Journal of Cancer|2001|1.6k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019
|The Lancet|2022|955
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884